Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Forestviewon Mar 26, 2024 10:19am
205 Views
Post# 35952842

RE:It does not make a lot of sense

RE:It does not make a lot of sense
Duster340 wrote: that nuance would burn through there own cash to let antibe carry on with the P2 trials. what if the drug is unsuccessful?  the burden of bringing the drug to a point where there would be potential partners or to a point were they could have got a financing deal was squandered by a poorly run company. nuance has got antibe over the barrel, if for some reason they were to throw out a life line it will not favor antibe or it's share holders.
glta


Here comes Duster spewing unsubstantiated claims that are not rooted in anything other than his personal opinion.  Again, if ATE goes bankrupt, Nuance is a creditor.  They will not get anything.  So, it's in their best interest to let P2 play out.  And, Mastermind was right, the reward has to be filed in Ontario court - that process hasn't started yet, and could take years to make its way through.  Plenty of time to let P2 play out.

Duster is ATEs biggest fan when he owns shares.  He does not have any now, so he spews nonsense - with bad grammar.  
<< Previous
Bullboard Posts
Next >>